Clinical Trials in Detroit

Showing 6401-6420 of 14,997 trials

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

NCT02620865

This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Bispecific antibody armed activated T-cells are the patient's own T cells that are coated with a bispecific antibody comprising 2 antibodies chemically joined together. These antibodies have specific targets and binding properties that may give the T cells a greater ability to seek out, attach to, and kill more cancer cells.

Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic Cancer+1 more

Barbara Ann Karmanos Cancer Institute2 participantsStarted Dec 2015

Detroit, Michigan, United States

TERMINATEDPhase 1< 1 mile

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04077021

CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subparts patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702 and efficacious regimen. Part Ia will explore every other other day dosing (QOD); Part Ib will explore weekly dosing (Q7D). In part II of the study, patients will be given the recommended part/phase 2 dose (RP2D) Q7D. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.

Metastatic Castration-Resistant Prostate Adenocarcinoma

Calibr, a division of Scripps Research22 participantsStarted Jul 2020

San Diego, California, United States • Baltimore, Maryland, United States • Detroit, Michigan, United States +2 more locations

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Find Trials by Condition in Detroit

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Fiber to Reduce Colon Cancer in Alaska Native People

HBV-HIV Coinfection Research Network

P3 Long Term Safety Study of Once Daily SB204 in Acne

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Glycemic Control and the Brain in Children With Type 1 Diabetes

Kenota 1 CWS Method Comparison Validation Study

Subject Evaluation of a 1064nm Diode Laser/RF